^{Zhitong Finance App News, Goli Pharmaceutical-B (01672) announced that two posters on its obesity pipeline oral small molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR three-target agonist polypeptide ASC37 will be displayed at ObesityWeek (ObesityWeek®) 2026.} The conference will be held in Washington DC from November 14 to 17, 2026.

“We are excited to present the latest pre-clinical developments in our strong and highly differentiated small molecule and peptide obesity pipeline at ObesityWeek ^® 2026,” said Dr. Wu Jinzi, founder, chairman of the board, and CEO of Geli. “These developments reflect our strong determination to develop highly differentiated treatment options for obesity.”

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.